Dear Ms. Holsmer-Brand:

Please refer to your Supplemental Biologics License Application (sBLA), dated February 18, 2019, received February 19, 2019, and your amendment, submitted under section 351(a) of the Public Health Service Act for ERBITUX® (cetuximab) injection, for intravenous use.

This Prior Approval labeling supplemental biologics application revises the Adverse Reactions, Clinical Trials Experience (6.1) subsection to add information on pulmonary embolism in patients with K-Ras Wild-type, EGFR-expressing, metastatic colorectal cancer treated with ERBITUX and FOLFIRI. This information was inadvertently deleted during the June 5, 2018, approval of S-269.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling text for the Prescribing Information, and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.
Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, please call Sharon Sickafuse, Senior Regulatory Health Project Manager, at 301-796-2320 or email sharon.sickafuse@fda.hhs.gov.

Sincerely,

\{See appended electronic signature page\}

Jeffery Summers, M.D.
Deputy Director for Safety
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research
ENCLOSURE:
  Content of Labeling
  Prescribing Information
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JEFFERY L SUMMERS
04/23/2019 12:35:55 PM